ISCP 2018, Kyoto – Full Program

Videos of many of the speakers and sessions is available below. Please click on the links highlighted in red below, where available, to view footage of the meeting.

Opening Remarks

Koji Hasegawa, Chair of 23rd ISCP Kyoto 2018, President of ISCP


Symposium:
Future Pharmacotherapy for Atherosclerosis: Basic Science for the Clinician

Chairpersons:

Kensuke Noma, Hiroshima, Japan
Morihiro Matsuda, Kure, Japan

Speakers:

Tatsuya Sawamura, Nagano, Japan: Modified Lipoproteins and LOX-1 in Cardiovascular Disease
Noboru Ashida, Kyoto, Japan: Role of inflammatory signaling in vascular calcification
Tetsuya Matoba, Fukuoka, Japan: Ezetimibe ameliorates coronary endothelial dysfunction through decreases in oxysterols
Koh Ono, Kyoto, Japan: SREBF1/MicroRNA-33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo


Joint Panel Discussion
ESC Working Group on Cardiovascular Pharmacotherapy:
Cardiac and Systemic Linkage for the Control of Hypertension

Chairpersons:

Heinz Drexel, Austria
Koji Hasegawa, Kyoto, Japan

Speakers:

Thomas Kahan, Sweden: Hypertensive heart disease
Stefan Agewall, Norway: Effective at last – The new glucose-lowering drugs that reduce CV events
Celso Amodeo, Brazil: Resistant hypertension
Junichi Oyama, Saga, Japan: Sleep apnea syndrome


Seminar supported by GSK: Pulmonary Hypertension

Chairpersons:

Atsushi Nakano, Japan

Speakers:

Carlos Jardim, Brazil
Hiromi Matsubara, Okayama, Japan


Panel Discussion:
Prevention of Atherosclerotic Events by Targeting Lipid Metabolism and Inflammation

Chairpersons:

Juan Carlos Kaski, UK
Celso Amodeo, Brazil

Speakers:

Watch video >
Heinz Drexel, Austria: PCSK9-inhibitors for which patient?

Watch video >
Masaaki Kawashiri, Kanazawa, Japan: Familiar Hypercholesterolemia

Watch video >
Alberto Lorenzatti, Argentina: Anti-inflammatory drugs: niche treatment or broad application?



Meet the Experts – pharmacotherapy challenges

Modulators:

Koji Hasegawa and Juan Carlos Kaski

Discussants:

George Dan, Thomas Kahan, Antoni Martinez Rubio, Felipe Martìnez.

Topics:

What is the best strategy for the management of HFpEF?
Should we use a same type of anticoagulant for all patients with AF?
PCSK9 Inhibitors: Indications and timing
Are β-blockers useful for the management of systemic hypertension?


Joint WHF/ISCP Plenary Session:
Global Cardiovascular Risk Management to Achieve ‘25 by 25’

Chairs and Modulators:

Jean-Luc Eiselé, CEO, World Heart Federation
Koji Hasegawa, President, ISCP

Opening Remarks:

Watch video >
Chuichi Kawai, Past President of World Heart Federation

Speakers and Discussants:

Watch video >
Katsuyuki Miura, Shiga, Japan:Global Epidemiology in Cardiovascular Risk Factors

Watch video >
Alvaro S. Liprandi, Argentina: Roadmaps to Achieve ‘25 by 25’ ─ Global and Regional Coalitions

Watch video >
Shinji Koba, Tokyo, Japan: The Role of Exercise for Cardiovascular Prevention

Watch video >
Maki Komiyama, Kyoto, Japan: Smoking and depression in Cardiovascular Disease

Watch video >
Edgardo Escobar, Chile: Telemedicine to Reduce Mortality in Heart Attacks

Watch video >
Plenary session Discussions


Henry N. Neufeld Memorial Award Lecture:

Watch video >
Lina Badimon, Catalan Institute of Cardiovascular Sciences (ICCC), Spanish National Research Council (CSIC)
Precision Medicine: Molecular Phenotyping in Cardiovascular Pharmacotherapy


Symposium:
Reprograming and Regeneration of the Heart: Basic Science for the Clinician

Chairpersons:

Tatsuya Morimoto, Shizuoka Japan
Shuhei Tomita, Osaka, Japan

Speakers:

Teruhisa Kawamura, Kyoto, Japan: Dissecting the Process of Metabolic Shift during iPS Cell Reprogramming
Junko Kurokawa, Shizuoka, Japan: Electrophysiological maturation of human iPS-derived cardiomyocytes
Masaki Ieda, Ibaraki, Japan: Direct Cardiac Reprogramming and Heart Regeneration
Takeru Makiyama, Kyoto, Japan: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies


Joint session of ISCP and ISCMF
Recent Advances in Cardiomyopathies, Myocarditis and Heart Failure

Chairpersons:

Mario Maranhao, Brazil
Peter Schultheiss, Germany

Speakers:

Akira Matsumori, Kyoto, Japan: New biomarkers of inflammation and cardiovascular risk
Peter Liu, Ottawa, Canada: Genetic and Protein Biomarkers in the Diagnosis and Management of Cardiomyopathies and Heart Failure
Andre Keren, Israel: Clinical implications of the new European definition of dilated cardiomyopathy
Leslie Cooper, USA: The Evolving Role for Nuclear Imaging in Unexplained Cardiomyopathy
Peter Schultheiss, Germany: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies


Seminar:
Up-to-date Topics of Atrial Fibrillation and Anti-coagulant Therapy

Chairperson:

Felipe Martinez, Argentina

Speaker:

Masaharu Akao, Kyoto, Japan: Risk stratification of atrial fibrillation in Asia
Dalmo Moreira, Brazil: Is there a role for the nonvit K antagonist in the prevention of atrial fibrillation? 


Symposium:
Pharmacotherapy and Life-style Modification for Heart Failure: the Present and the Future

Chairpersons:

Shigetake Sasayama, Kyoto, Japan
Yasushi Fujio, Osaka, Japan

Speakers:

Sang Hong Baek, Korea: Myocardial fibrosis and new options for treatment
Felipe Martinez, Argentina: New drugs in heart failure: more of the same or the beginning of a new era?
Takuya Kishi, Fukuoka, Japan: Cardiac linkage with brain and autonomic nervous system


Symposium:
Cardiovascular Imaging Guiding Pharmacotherapy

Chairpersons:

Alberto Lorenzatti, Argentina
Masataka Sata, Tokushima, Japan

Speakers:

Augusto Gallino, Switzerland: Role of imaging in developing new drugs
Takashi Akasaka, Wakayama, Japan: Optical coherence tomography
Mitsuyasu Terashima, Aiti, Japan: Intravascular Ultrasound


Panel Discussion:
Controversies in Anti-coagulant Therapy in Atrial Fibrillation and Venous Thromboembolism

Chairpersons:

George A. Dan, Romania
Takanori Ikeda, Tokyo, Japan

Speakers:

Ali Oto, Turkey: Risk stratification of stroke in AF
Antoni Martinez-Rubio Barcelona, Spain: DOAC for AF
Shinji Hisatake, Tokyo, Japan: DOAC for VTE


Panel Discussion
Treatment of Atrial Fibrillation: the Place of Antiarrhythmic Drugs

Chairpersons:

Ali Oto, Turkey
Atsushi Sugiyama, Tokyo, Japan

Speakers:

George A. Dan, Romania: Antiarrhythmic drugs
Naohiko Takahashi, Oita, Japan: Inflammation in AF


Joint Workshop with Asian Pacific Society of Cardiology (APSC)
Prediction and Prevention of Sudden Cardiac Death and Syncope

Chairpersons:

Jiunn-Lee Lin, Taiwan (from APSC)
Nannette R. Rey, Philippine (from ISCP)

Speakers:

Watch video >
Anca Dan, Romania: Syncope: Diagnosis and risk stratification

Watch video >
Naohiko Takahashi, Oita, Japan: Sudden cardiac death in J-wave syndrome

Watch video >
Takanori Ikeda, Tokyo, Japan: Prediction of sudden cardiac death

Watch video >
Joint workshop: Discussion


Award Ceremony for Best Abstract Presentation

Cavin-2 Deficiency Attenuates Cardiac Fibrosis and Dysfunction in Pressure-overloaded Hearts
Yusuke Higuchi, Takehiro Ogata, Masahiro Nishi, Satoaki Matoba

Comparative Analysis of the Effects EPA and DHA on Cultured Cardiomyocyte
Ayumi Katayama, Masafumi Funamoto, Kana Shimizu1, Mai Gempei, Yoichi Sunagawa, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto

3D Ultrastructure of the “Arrhythmogenic” Purkinje Fibre-ventricular Junction in Rabbit Hearts
Shu Nakao, Il-Young Oh, Luke Stuart, Hiren Sitpura, Joseph Yanni, Sunil JSR Logantha, Xue Cai, Tobias Starborg, Halina Dobrzynski, Ashraf Kitmitto, Mark R Boyett


Closing Remarks

Augusto Gallino, Chair, 24th ISCP Switzerland 2019

Please visit the ISCP 2019 website for details of the 2019 meeting in Lugano


Symposium
Drug Management of Coronary Vasospasm, Microvascular Angina and Takotsubo Cardiomyopathy

Chairpersons:

Masatoshi Fujita, Kyoto, Japan
Masataka Sata, Tokushima, Japan

Speakers:

Juan Carlos Kaski, UK: Microvascular angina
Sang Hong Baek, Korea: Coronary vasospasm
Yoshihiro Akashi, Kanagawa, Japan: Takotsubo cardiomyopathy


Joint Symposium with Asian Pacific Society of Cardiology (APSC)
Biomarkers to Predict Acute Coronary Syndrome, Atherosclerosis and Heart Failure

Chairpersons:

San-Jou Yeh, Taiwan (from APSC)
Jorge A. Sison, Philippine (from ISCP)

Speakers:

Bernard MY Cheung, Hong Kong: Biomarkers for acute coronary syndrome – are they good enough?
Augusto Gallino, Switzerland
Hiromichi Wada, Kyoto, Japan: Vascular endothelial growth factor-C and mortality in patients with suspected coronary artery disease


Symposium:
Anti-thrombotic Therapy during and after Coronary Intervention

Chairpersons:

Augusto Gallino, Switzerland
Doreen Tan, Singapore

Speakers:

Bernard MY Cheung, Hong Kong: Resolving the controversy on optimal duration of dual antiplatelet therapy after coronary intervention
Antoni Martinez-Rubio, Barcelona, Spain: DOAC in coronary artery disease
Isao Taguchi, Saitama, Japan: Optimal anti-thrombotic therapy after PCI


Governor’s Meeting


World Tobacco No Day Memorial Session:
Tobacco and heart disease

Chairperson:

Keijiro Saku, Kyoto Japan
Tatsuya Morimoto, Shizuoka Japan

Speakers and Discussants:

Toyoaki Murohara, Aichi Japan: Tobacco and cardiovascular disease
Rei Goto, Tokyo Japan: Cost-benefit Effectiveness on Smoking Cessation
Lisa Demos, Australia: Pharmacotherapy and Australian initiatives for smoking cessation


Symposium:
Cardiac metabolism and mitochondria

Chairperson:

Satoaki Matoba, Kyoto Japan
Hiroshi Kondo, Kyoto Japan

Speakers:

Osamu Yamaguchi, Ehime, Japan: Mitochondria degradation as a novel therapeutic target for heart failure
Masaya Tanno, Hokkaido, Japan: Regulation of mitochondrial GSK-3β activity by kinases, phosphatases and a deacetylase: a key determinant for mitochondrial permeability transition
Ippei Shimizu, Niigata Japan: The pathological role of brown adipose tissue dysfunction in cardio-metabolic disorders
Atsushi Hoshino, Kyoto Japan: Essential mitochondrial components to induce mitophagy